FDA Approves First Generic Fluticasone Propionate Inhaler, Boosting Affordable Asthma Care

The FDA has authorized the first generic version of fluticasone propionate (Flovent HFA; GSK) inhalation aerosol, marking a promising development in asthma treatment access.¹ Approved for maintenance therapy in patients aged 4 years and older, the generic metered‑dose inhaler delivers the same active ingredient and safety profile as the brand product but is expected to expand affordability and availability of a key anti‑inflammatory therapy for millions of individuals living with asthma.

"Today's approval of the first generic fluticasone propionate inhalation aerosol represents an important step in expanding access to affordable asthma treatment," said Iilun Murphy, MD, Director of the Office of Generic Drugs, Center for Drug Evaluation and Research (CDER), in a statement. "Generic medications provide patients with safe, effective, and more affordable treatment options. The FDA remains committed to facilitating the development and approval of generic drugs to increase patient access to essential medicines."

Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals, was given the generic inhalation aerosol approval after they met the FDA’s requirements for bioequivalence and therapeutic equivalence to Flovent HFA.

Asthma affects nearly 25 million Americans, including approximately 4.6 million children, and accounts for an estimated 10 million asthma attacks and about 3500 deaths annually in the US. By adding a generic version of a widely used asthma controller, the FDA aims to enhance affordability and broaden treatment options for patients and providers alike.

Under the FDA’s regulatory framework, the prescribing information for fluticasone propionate inhalation aerosol mirrors the brand label’s contraindications, warnings, and precautions, including guidance on proper use and potential adverse effects such as oropharyngeal candidiasis and immunosuppression. As with the branded version, the generic is not intended for relief of acute bronchospasm or status asthmaticus.

In addition to meeting generic approval standards, Glenmark’s product has been designated under the FDA’s Competitive Generic Therapy pathway as a first approved applicant, making the company eligible for 180 days of market exclusivity once the product is commercialized.² This exclusivity is designed to incentivize the development of generic versions of complex products with limited competition, particularly in categories like inhalation therapies that historically have posed technical manufacturing challenges.

The market for Flovent HFA 44 mcg is significant, with annual sales in the US estimated at about $520 million, highlighting both the clinical importance of the medication and the potential impact of the generic entrant on pricing and access. Glenmark plans to begin distribution of the generic inhaler in the US starting in March 2026, with commercial availability expected to follow soon thereafter.

For patients and clinicians, the availability of a generic Flovent HFA formulation represents a welcome expansion of treatment choices, particularly for individuals who may face financial barriers to ongoing asthma management. As insurers often encourage generic substitution when available, the new approval could lead to lower out-of-pocket costs and fewer disruptions in controller therapy adherence.

“Between 5% and 10% of Americans and just over 6% of children have an asthma diagnosis,” said Tracy Beth Høeg, MD, PhD, acting director, CDER, in a statement. ¹ “Flovent is a highly effective preventive medication, which, when used regularly, has been linked to a reduction in asthma-related hospitalizations and admissions to intensive care. As of today, with the approval of the first generic metered-dose inhaler form of the medication, we anticipate increased availability and reduced costs of treating this prevalent and at times very serious condition. I am proud of the work CDER has done to bring this generic to market.”

References

1. FDA approves first generic of Flovent HFA for treatment of asthma. FDA. March 3, 2026. Accessed March 4, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-generic-flovent-hfa-treatment-asthma

2. Glenmark Specialty SA receives US FDA approval for fluticasone propionate inhalation aerosol USP, 44 mcg per actuation, with 180-day competitive generic therapy exclusivity. Glenmark Pharmaceuticals. March 4, 2026. Accessed March 4, 2026. https://www.prnewswire.com/news-releases/glenmark-specialty-sa-receives-us-fda-approval-for-fluticasone-propionate-inhalation-aerosol-usp-44-mcg-per-actuation-with-180-day-competitive-generic-therapy-exclusivity-